FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012336428> ?p ?o ?g. }

• W2012336428 endingPage "121" @default.
• W2012336428 startingPage "117" @default.
• W2012336428 abstract "Objective To evaluate the efficacy and safety of solifenacin in the management of irritative symptoms after transurethral resection of bladder tumors (TURBTs) with subsequent intravesical chemotherapy. Methods A total of 116 patients undergoing TURBT were randomly allocated into 2 groups, 58 patients in each group. Group 1 patients received solifenacin 5 mg, 6 hours before surgery and 5 mg per day, after surgery for 2 weeks, whereas group 2 patients received a placebo. Patients with low-risk non–muscle-invasive bladder cancer received immediate postoperative instillation of epirubicin. Patients with medium- or high-risk non–muscle-invasive bladder cancer received postoperative instillation twice within 2 weeks, once immediately following the operation and once on the eighth postoperative day. All patients completed bladder diaries before surgery, on the 1st, 7th, and 14th days after removal of the catheter with overactive bladder symptom scores completed preoperatively, and on the 7th and 14th days. Additionally, the incidence and severity of catheter-related bladder discomfort were recorded at 6, 12, 24, 48, and 72 hours after the surgery. Results The incidence and the severity of catheter-related bladder discomfort in group 1, compared with group 2, were significantly reduced (P <.05). There was a significant difference in overactive bladder symptom scores between the 2 groups (5.67 vs 7.86; P <.001). Episodes of daytime, frequency, nocturia, urgency, and urge urinary incontinence in group 1 were also significantly lower than in group 2 (P <.05). Conclusion This study demonstrates that solifenacin can be beneficial for the management of irritative symptoms after TURBT with subsequent intravesical chemotherapy. To evaluate the efficacy and safety of solifenacin in the management of irritative symptoms after transurethral resection of bladder tumors (TURBTs) with subsequent intravesical chemotherapy. A total of 116 patients undergoing TURBT were randomly allocated into 2 groups, 58 patients in each group. Group 1 patients received solifenacin 5 mg, 6 hours before surgery and 5 mg per day, after surgery for 2 weeks, whereas group 2 patients received a placebo. Patients with low-risk non–muscle-invasive bladder cancer received immediate postoperative instillation of epirubicin. Patients with medium- or high-risk non–muscle-invasive bladder cancer received postoperative instillation twice within 2 weeks, once immediately following the operation and once on the eighth postoperative day. All patients completed bladder diaries before surgery, on the 1st, 7th, and 14th days after removal of the catheter with overactive bladder symptom scores completed preoperatively, and on the 7th and 14th days. Additionally, the incidence and severity of catheter-related bladder discomfort were recorded at 6, 12, 24, 48, and 72 hours after the surgery. The incidence and the severity of catheter-related bladder discomfort in group 1, compared with group 2, were significantly reduced (P <.05). There was a significant difference in overactive bladder symptom scores between the 2 groups (5.67 vs 7.86; P <.001). Episodes of daytime, frequency, nocturia, urgency, and urge urinary incontinence in group 1 were also significantly lower than in group 2 (P <.05). This study demonstrates that solifenacin can be beneficial for the management of irritative symptoms after TURBT with subsequent intravesical chemotherapy." @default.
• W2012336428 created "2016-06-24" @default.
• W2012336428 creator A5011378633 @default.
• W2012336428 creator A5024005604 @default.
• W2012336428 creator A5024287203 @default.
• W2012336428 creator A5033903580 @default.
• W2012336428 creator A5043069455 @default.
• W2012336428 creator A5050018283 @default.
• W2012336428 creator A5062081744 @default.
• W2012336428 creator A5063317733 @default.
• W2012336428 creator A5073216396 @default.
• W2012336428 creator A5082376921 @default.
• W2012336428 creator A5089966579 @default.
• W2012336428 date "2014-07-01" @default.
• W2012336428 modified "2023-10-15" @default.
• W2012336428 title "Solifenacin Is Able to Improve the Irritative Symptoms After Transurethral Resection of Bladder Tumors" @default.
• W2012336428 cites W1585489386 @default.
• W2012336428 cites W161953857 @default.
• W2012336428 cites W1649756892 @default.
• W2012336428 cites W1978083855 @default.
• W2012336428 cites W1984503699 @default.
• W2012336428 cites W1996122945 @default.
• W2012336428 cites W2005576596 @default.
• W2012336428 cites W2019119348 @default.
• W2012336428 cites W2024813481 @default.
• W2012336428 cites W2030691442 @default.
• W2012336428 cites W2055589884 @default.
• W2012336428 cites W2060193818 @default.
• W2012336428 cites W2092473900 @default.
• W2012336428 cites W2092749677 @default.
• W2012336428 cites W2131173377 @default.
• W2012336428 cites W2136500714 @default.
• W2012336428 cites W2142148858 @default.
• W2012336428 cites W4247900695 @default.
• W2012336428 cites W4253168713 @default.
• W2012336428 doi "https://doi.org/10.1016/j.urology.2014.02.034" @default.
• W2012336428 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24785989" @default.
• W2012336428 hasPublicationYear "2014" @default.
• W2012336428 type Work @default.
• W2012336428 sameAs 2012336428 @default.
• W2012336428 citedByCount "25" @default.
• W2012336428 countsByYear W20123364282015 @default.
• W2012336428 countsByYear W20123364282017 @default.
• W2012336428 countsByYear W20123364282018 @default.
• W2012336428 countsByYear W20123364282019 @default.
• W2012336428 countsByYear W20123364282020 @default.
• W2012336428 countsByYear W20123364282021 @default.
• W2012336428 countsByYear W20123364282022 @default.
• W2012336428 countsByYear W20123364282023 @default.
• W2012336428 crossrefType "journal-article" @default.
• W2012336428 hasAuthorship W2012336428A5011378633 @default.
• W2012336428 hasAuthorship W2012336428A5024005604 @default.
• W2012336428 hasAuthorship W2012336428A5024287203 @default.
• W2012336428 hasAuthorship W2012336428A5033903580 @default.
• W2012336428 hasAuthorship W2012336428A5043069455 @default.
• W2012336428 hasAuthorship W2012336428A5050018283 @default.
• W2012336428 hasAuthorship W2012336428A5062081744 @default.
• W2012336428 hasAuthorship W2012336428A5063317733 @default.
• W2012336428 hasAuthorship W2012336428A5073216396 @default.
• W2012336428 hasAuthorship W2012336428A5082376921 @default.
• W2012336428 hasAuthorship W2012336428A5089966579 @default.
• W2012336428 hasConcept C120665830 @default.
• W2012336428 hasConcept C121332964 @default.
• W2012336428 hasConcept C121608353 @default.
• W2012336428 hasConcept C126322002 @default.
• W2012336428 hasConcept C126894567 @default.
• W2012336428 hasConcept C141071460 @default.
• W2012336428 hasConcept C142724271 @default.
• W2012336428 hasConcept C204787440 @default.
• W2012336428 hasConcept C2777333188 @default.
• W2012336428 hasConcept C2778941218 @default.
• W2012336428 hasConcept C2779502394 @default.
• W2012336428 hasConcept C2780352672 @default.
• W2012336428 hasConcept C2781267111 @default.
• W2012336428 hasConcept C61511704 @default.
• W2012336428 hasConcept C71924100 @default.
• W2012336428 hasConcept C77411442 @default.
• W2012336428 hasConceptScore W2012336428C120665830 @default.
• W2012336428 hasConceptScore W2012336428C121332964 @default.
• W2012336428 hasConceptScore W2012336428C121608353 @default.
• W2012336428 hasConceptScore W2012336428C126322002 @default.
• W2012336428 hasConceptScore W2012336428C126894567 @default.
• W2012336428 hasConceptScore W2012336428C141071460 @default.
• W2012336428 hasConceptScore W2012336428C142724271 @default.
• W2012336428 hasConceptScore W2012336428C204787440 @default.
• W2012336428 hasConceptScore W2012336428C2777333188 @default.
• W2012336428 hasConceptScore W2012336428C2778941218 @default.
• W2012336428 hasConceptScore W2012336428C2779502394 @default.
• W2012336428 hasConceptScore W2012336428C2780352672 @default.
• W2012336428 hasConceptScore W2012336428C2781267111 @default.
• W2012336428 hasConceptScore W2012336428C61511704 @default.
• W2012336428 hasConceptScore W2012336428C71924100 @default.
• W2012336428 hasConceptScore W2012336428C77411442 @default.
• W2012336428 hasIssue "1" @default.
• W2012336428 hasLocation W20123364281 @default.
• W2012336428 hasLocation W20123364282 @default.
• W2012336428 hasOpenAccess W2012336428 @default.
• W2012336428 hasPrimaryLocation W20123364281 @default.

• next